[3aR-(3aα,4α,6α,6aα)]-2-[6-[7-Amino-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy]ethanol | 274693-45-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: [3aR-(3aα,4α,6α,6aα)]-2-[6-[7-Amino-5-[(3,3,3-trifluoropropyl)thio]-3H-1,2,3-triazolo[4,5-d]-pyrimidin-3-yl]-tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yloxy]ethanol
• 英文别名: 2-[[(3aR,4S,6R,6aS)-6-[7-amino-5-(3,3,3-trifluoropropylsulfanyl)triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol
• CAS: 274693-45-7
• 化学式: C₁₇H₂₃F₃N₆O₄S
• 分子量: 464.469
• InChiKey: SJARPPOMJSWNSA-LLHIFLOGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  156
• 氢给体数：
  2
• 氢受体数：
  13

文献信息

• Novel compounds
  申请人：AstraZeneca AB

  公开号：US20030144305A1

  公开（公告）日：2003-07-31

  The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.

  本发明提供了新的三唑[4,5-d]嘧啶化合物，它们作为药物的用途，包含它们的组合物以及它们的制备过程。
• Intermediates
  申请人：AstraZeneca AB

  公开号：EP2322513A2

  公开（公告）日：2011-05-18

  The invention provides compounds for the preparation of new triazolo[4,5-d]pyrimidine compounds of formula (I),

  本发明提供了用于制备新的式（I）三唑并[4,5-d]嘧啶化合物的化合物、
• Treatment of kidney diseases associated with elevated AVP
  申请人：THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

  公开号：US10614684B2

  公开（公告）日：2020-04-07

  Disclosed are methods for treating kidney disease including autosomal dominant polycystic kidney disease (ADPKD) in a subject, comprising the step of administering to the subject a composition comprising a therapeutically effective amount of ticagrelor or a derivative thereof, thereby treating ADPKD. Disclosed are methods of decreasing arginine vasopressin (AVP) production in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production. Disclosed are methods for treating dilutional hyponatremia in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production.

  公开了治疗受试者肾脏疾病包括常染色体显性多囊肾病（ADPKD）的方法，包括向受试者施用包含治疗有效量替卡格雷或其衍生物的组合物的步骤，从而治疗ADPKD。公开了减少受试者精氨酸加压素（AVP）分泌的方法，包括向受试者施用包含有效量替卡格雷的组合物的步骤，从而减少AVP的分泌。公开了治疗受试者稀释性低钠血症的方法，包括向受试者施用包含有效量替卡格雷的组合物的步骤，从而减少AVP的产生。
• NOVEL TRIAZOLO(4,5-D)PYRIMIDINE COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1135391B1

  公开（公告）日：2004-03-17
• TREATMENT OF KIDNEY DISEASES ASSOCIATED WITH ELEVATED AVP
  申请人：Department of Veterans Affairs

  公开号：US20180214450A1

  公开（公告）日：2018-08-02

  Disclosed are methods for treating kidney disease including autosomal dominant polycystic kidney disease (ADPKD) in a subject, comprising the step of administering to the subject a composition comprising a therapeutically effective amount of ticagrelor or a derivative thereof, thereby treating ADPKD. Disclosed are methods of decreasing arginine vasopressin (AVP) production in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production. Disclosed are methods for treating dilutional hyponatremia in a subject comprising the step of administering to the subject a composition comprising an effective amount of ticagrelor, thereby decreasing AVP production.